Japanese researchers push to commercialize 'happiness hormone' nasal spray drug for autism

Japan Times

A group of researchers in Japan is hoping to make available for use as a nasal spray a drug to improve symptoms of autism spectrum disorder, or ASD.

The group, led by Professor Hidenori Yamasue of Hamamatsu University School of Medicine, is conducting a clinical trial of the treatment that includes oxytocin, also known as the “happiness hormone.”

The oxytocin spray is drawing attention from ASD patients and their families throughout Japan because an effective treatment has yet to be established for ASD, which is marked by issues relating to interpersonal communication, empathy and cooperation with others.

ASD, which includes autism and Asperger’s syndrome, affects one in every 100 people, according to Yamasue. Symptoms generally appear between the ages of 2 and 3, but many people are not diagnosed until they reach adulthood.

ASD affects more men than women. Based on this, Yamasue came up with a theory that oxytocin — a hormone that plays a role in womb contractions and the release of breast milk — may be linked to patients’ readiness to cooperate.

During the trial, adult male subjects showed an improvement in their communicative ability after inhaling oxytocin through the nose. Part of the brain that controls emotional understanding grew more active after the inhalation.

The number of people diagnosed with ASD is on the rise in Japan as public awareness of the disorder has increased.

While the disorder has drawn wider public attention, an effective treatment remains elusive.

“ASD patients, their families and all of society suffer heavy burdens,” Yamasue said, stressing his wish to develop a remedy as soon as possible.

Last month, Yamasue won an award from the Japan Agency for Medical Research and Development, or AMED, for young researchers who have made contributions to the medical field.

The oxytocin spray, which is in a Phase 2 trial, is being tested at seven universities across the country.

Yamasue said the group aims to put the treatment into practical use by 2023 after confirming its safety and effects.

From Japan Times

Related Articles

The firm whose staff are all autistic

On first inspection it seems like any other Los Angeles-based company, with tasteful art on the white walls an ..

read more

Gut bacteria may offer a treatment for autism

Autism affects people’s social behaviour and communication, and may impair their ability to learn things. Al ..

read more

This Santa understands kids with autism...because he has it, too

Kerry Magro will always remember the first time he met Santa — and it’s not a happy memory. Things were ..

read more

Our Support Community

Join our free support community and connect with thousands of other families and individuals touched by ASD. Find out what’s working for others, coping strategies, and life guides from others living what you’re going through now. Click here to join for free!

Resources in Your Area

Looking for autism resources nearby? Check our listings for professionals and services that might help.

Post your services | Help out in general


9th World Rett Syndrome Congress
Surfers Paradise, QLD - Australia
Sep-30-2020 - 09:00 am
The Rett Syndrome Association of Australia (RSAA)email rettaust@bigpond.comwishes to draw attention to the fact that it is staging the 9th World Rett Syndrome Congress i ..
Go to Event site

view all events